21/04/2017 18:39:45

MPI increases its share capital with nominal DKK 6,190 as a result of exercise of 123,800 warrants

Hoersholm; April 21st 2017 - Medical Prognosis Institute A/S (MPI) announced today that, as a consequence of an exercise of warrants the share capital has been increased by nominal DKK 6,190 and the number of shares has been increased with 123,800.

The increase is affected without any pre-emption rights for the existing shareholders of the company or others. The shares are subscribed in cash at a price of DKK 0.52 per share of nominally DKK 0.05.

Proceeds to the company are DKK 64,376.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2016. MPI's current share capital amounts to DKK 1,174,452 and will after the capital increase be DKK 1,180,642. The capital increase is expected to be finalized shortly.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)

MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA.

The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About MPI

Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

For further information, please contact:

CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD                              Ulla Hald Buhl, IR & Communication

E-mail: pbj@medical-prognosis.com                                                          E-mail: uhb@medical-prognosis.com

Telephone: +45 21 60 89 22                                                                       Telephone +45 21 70 10 49

This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 21

st

2017.

Certified Advisor:

Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sweden

MPI - Increases its share capital due to warrant exercise April 2017


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medical Prognosis Institute via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Jun
VWS
Normal 0 false false false DA X-NONE X-NONE ..
41
21 Jun
BAVA
Men hvis man ikke efterrationalisere mere end, "nå", så er der da gode penge at hente i bankerne, ve..
27
24 Jun
ZEAL
Tirsdag den 7. febuarar i år udsendte det amerikanske National Institute of Health  (NIH) en pressem..
21
22 Jun
VELO
Må sige at det er ekstremt svært at finde ud af hvad Veloxis har at byde på, og om der er gode mulig..
19
19 Jun
BEO-SDB
God eftermiddag,   Efter at have set på de forskellige meninger og argumenter på FB, EI, Avanza og L..
18
23 Jun
BAVA
Jeg kan se at nogle vælger at sælge lidt ud - det kan jeg for så vidt godt forstå - jeg vil dog uænd..
17
19 Jun
BAVA
Nyhedsflowet fra Bavarian resten af 2017 bliver enormt spændende. Husk at det er Biotek og nyheder i..
17
21 Jun
BAVA
Fra 0,77% til ca. 0,4%.   Derfor faldt den ikke tilbage i går. De har købt ca 120.000 aktier.   Det ..
15
21 Jun
VWS
Aarhus, Danmark, 2017-06-21 16:17 CEST (GLOBE NEWSWIRE) --     I forbindelse med at OOO Fortum Energ..
14
19 Jun
PNDORA
Jeg har i nogen tid undret mig over at Goodwrench gives så meget opmærksomhed. Investerer han i virk..
12

Alliance Trust PLC : Transaction in Own Shares

14/06/2017 07:00:13
14 June 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 13 June 2017 the Company purchased for cancellation 209,000 ordinary shares of 2.5p each at a price of 708.0748p per share.  Therefore, the total number of voting rights in the Company is now 354,575,762.    The above figure (354,575,762) may be used by shareholder..

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

13/06/2017 15:20:46
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Quarterly Update for the Quarter to 30 April 2017

13/06/2017 12:50:10
13 June 2017 ICG Enterprise Trust Plc Quarterly Update For the quarter to 30 April 2017 Highlights Share price Total Return1 of 5.7% for the quarter and 39.9% for the 12 months to 30 April 2017 Net asset value per share Total Return1 of 0.6% for the quarter and 19.9% for the 12 months The Portfolio1 is valued at £54..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency
2
New Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML
3
Survey finds U.S. mayors taking action on climate protection, and planning for more
4
Norway Royal Salmon ASA: Share-based incentive scheme - Mandatory notification of trade
5
MAYORS SAY: LOOK TO CITIES FOR INSPIRED LEADERSHIP AND REAL RESULTS IN THE FACE OF DEEP NATIONAL FRUSTRATION WITH WASHINGTON

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 June 2017 09:49:58
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170623.1 - EUROWEB4 - 2017-06-25 10:49:58 - 2017-06-25 09:49:58 - 1000 - Website: OKAY